Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECIM
2023-504302-11-02Phase 2Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, ipilimumab, carboplatin, cisplatin and pemetrexed in pleural mesothelioma, sponsored by Antwerp University Hospital. Primary endpoint: Rate of success (composite feasibility, efficacy, and safety). Planned start Mar 2025; status: authorised.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2023-504302-11-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504302-11-02.